Few areas of psychiatric research have undergone as dramatic a rehabilitation in scientific standing as the study of psychedelic compounds. Once synonymous with the cultural upheavals of the 1960s and subsequently buried under decades of regulatory prohibition, psilocybin, MDMA, ketamine, and their pharmacological relatives have re-entered the mainstream of clinical investigation with a momentum that would have seemed implausible a generation ago. As the Journal of Global Health Neurology and Psychiatry opens its fifth volume, we examine this so-called psychedelic renaissance with the lens that defines our mission: not only asking what these compounds can do, but asking for whom, under what conditions, at what cost, and within whose cultural and health system realities they are likely to be safe, effective, and accessible.

The treatment gap for severe psychiatric disorders — depression, PTSD, addiction, and end-of-life existential distress among them — remains one of the defining failures of global mental health care. Existing pharmacological and psychological treatments, while effective for many, leave a substantial proportion of patients without adequate relief. It is against this backdrop of unmet need that the renewed investigation of psychedelic-assisted therapy has attracted both scientific excitement and, more recently, significant commercial and regulatory attention.

The Evidence Base: What We Now Know

The past decade has produced a body of evidence that, while still maturing, justifies serious scientific engagement. Randomized controlled trials of psilocybin-assisted therapy for treatment-resistant depression have reported response rates substantially higher than those achieved with conventional antidepressants, with effect sizes that have commanded attention in leading journals.1 Phase 3 trials of MDMA-assisted therapy for PTSD, conducted across multiple sites in North America and Europe, demonstrated significant reductions in PTSD symptom severity compared to placebo-controlled therapy, leading to regulatory submissions in the United States and several European jurisdictions.2

Ketamine and its S-enantiomer esketamine occupy a somewhat different regulatory space, having achieved approved status in several countries for treatment-resistant depression and, in intranasal formulation, for acute suicidality. The rapidity of ketamine’s antidepressant effect — measurable within hours rather than the weeks required by conventional antidepressants — has opened new clinical possibilities for acute psychiatric crises.3 Meanwhile, research into psilocybin for alcohol use disorder, anorexia nervosa, obsessive-compulsive disorder, and the existential distress of terminal illness has expanded the potential therapeutic footprint of this compound considerably.

Neuroscience of Transformation: What Psychedelics Do to the Brain

The mechanistic picture has grown considerably more sophisticated. Classic psychedelics such as psilocybin act primarily as agonists at serotonin 5-HT2A receptors, inducing a state of increased neural entropy — a transient dissolution of the hierarchical predictive processing that ordinarily constrains perception and cognition — that appears to facilitate psychological flexibility and the disruption of maladaptive rumination patterns.4 Neuroimaging studies have demonstrated that psilocybin reduces activity in the default mode network, a set of brain regions implicated in self-referential thinking and characteristic of the rigid, negatively-valenced cognitive patterns seen in depression and PTSD.

The therapeutic model in most trials is not pharmacology alone: psychedelic compounds are administered in conjunction with structured psychological preparation and integration sessions, within a carefully designed set and setting. This integration of pharmacology and psychotherapy complicates both the mechanistic interpretation of results and their practical translatability — a point to which we return below.

Regulatory Momentum and Its Limits

The regulatory landscape has shifted substantially. Australia became the first country to formally approve psychedelic-assisted therapy at the national level, authorizing psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression from July 2023.5 Several US states have enacted or advanced ballot initiatives permitting regulated access to psilocybin services. In Europe, regulatory pathways are being actively explored. This regulatory momentum reflects genuine scientific progress — but it also reflects commercial pressures and advocacy dynamics that do not always align perfectly with the evidentiary standards we would ordinarily require before widespread clinical deployment.

The partial clinical hold imposed by the US Food and Drug Administration on MDMA-assisted therapy following its advisory committee review in 2024, citing concerns about trial design, functional unblinding, and the handling of adverse events in the pivotal trials, served as a salutary reminder that enthusiasm — however well-founded — does not substitute for rigorous evaluation. The scientific community would do well to hold the psychedelic renaissance to the same evidentiary standards applied to any other emerging therapeutic class.

The Global Equity Blind Spot

It is here that the perspective of a journal dedicated to global health becomes most distinctly relevant — and most critical. The psychedelic renaissance, as it is currently unfolding, is overwhelmingly a phenomenon of wealthy, English-speaking, predominantly white populations and institutions. The clinical trials that have generated excitement were conducted almost exclusively in high-income settings; their participants were drawn from populations with access to well-resourced research centres, cultural familiarity with psychotherapy as a treatment modality, and the luxury of time required for preparation and integration sessions that may span weeks.

The treatment model being commercialized in high-income countries — a medically supervised session of six to eight hours, preceded by multiple preparatory visits and followed by structured integration, delivered by two trained therapists in a carefully designed therapeutic environment — carries a cost per patient that places it beyond the reach of any realistic public health system in an LMIC. If psychedelic-assisted therapy becomes the exclusive province of affluent patients in wealthy countries, it will represent yet another chapter in the long history of psychiatric innovation that widens rather than narrows the global mental health treatment gap.

There is also a cultural dimension that the field has been slow to reckon with. Psychedelic compounds do not enter a culturally neutral space. Psilocybin mushrooms, ayahuasca, peyote, and other plant medicines have been central to the spiritual and healing practices of Indigenous communities in the Americas and elsewhere for centuries. The appropriation of these traditions — stripped of their cultural context, repackaged as psychiatric treatment, and monetized by commercial enterprises — raises profound questions of intellectual property, cultural respect, and distributive justice that the psychedelic research community cannot indefinitely defer.6

Safety, Vulnerability, and the Risks of Premature Deployment

Enthusiasm for psychedelic-assisted therapy must be tempered by clear-eyed attention to its risks. Psychedelic experiences can be profoundly destabilizing, particularly for individuals with personal or family histories of psychosis or bipolar disorder. Reports of adverse events in both trial and real-world settings — including prolonged psychological distress, hallucinogen persisting perception disorder, and, in a small number of cases, the exploitation of therapeutically vulnerable patients by unscrupulous practitioners — have underscored the importance of rigorous screening, trained personnel, and robust regulatory oversight.7

In settings where psychiatric diagnosis is unreliable, where follow-up care is unavailable, and where the therapeutic relationship cannot be adequately monitored or regulated, the risk-benefit calculus changes substantially. This is not an argument against exploring the potential of these compounds in LMIC settings — it is an argument for doing so carefully, collaboratively, and with genuine attention to local context rather than simply transplanting protocols developed elsewhere.8

An Agenda for Global Psychedelic Research

The Journal of Global Health Neurology and Psychiatry welcomes rigorous research on psychedelic-assisted therapy that engages seriously with global equity. This means trials that recruit participants from diverse cultural and socioeconomic backgrounds; implementation research that explores simplified, task-sharing-compatible delivery models; ethnographic and qualitative work that examines the experience of psychedelic therapy across cultural contexts; and pharmacoeconomic analyses that honestly assess what treatment models are scalable within the realities of LMIC health systems.

We also call for a frank disciplinary conversation about what the psychedelic renaissance means for the communities whose traditional knowledge it draws upon — and for international frameworks that ensure those communities participate equitably in any benefits that flow from the commercialization of that knowledge.

The history of psychiatry includes many enthusiasms that did not survive contact with rigorous science and diverse populations. The psychedelic renaissance may prove genuinely transformative — or it may prove more limited and more culturally specific than its proponents currently believe. What it must not do is repeat the historical pattern of psychiatric innovation that serves the few while ignoring the many. This journal exists, in part, to ensure it does not.